2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Interactive Research And Development: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) Bedaquiline 100 MG, Delamanid 50 MG Oral Tablet, Clofazimine 100 MG Oral Capsule - Tuberculosis, Multidrug-Resistant, Tuberculosis | Phase 3 | Completed | Médecins Sans Frontières, France | 323 | 2020-04-06 | 2025-02-10 |
| Evaluating Newly Approved Drugs for Multidrug-resistant TB Bedaquiline, Delamanid, Clofazimine - Tuberculosis, Multidrug-Resistant, Infection, Bacterial | Phase 3 | Completed | Médecins Sans Frontières, France | 754 | 2016-12-01 | 2025-02-10 |
Bacterial Infections (2) · Tuberculosis (2) · Tuberculosis, Multidrug-Resistant (2) · Tuberculosis, Pulmonary (2) · Extensively Drug-Resistant Tuberculosis (1) · Gram-Positive Bacterial Infections (1) · Mycobacterium Infections (1)
Clofazimine (2) · Linezolid (2) · OPC-67683 (2) · bedaquiline (2) · Levofloxacin (1) · Moxifloxacin (1) · Pyrazinamide (1) · Tablets (1)
India (2) · Kazakhstan (2) · Lesotho (2) · Pakistan (2) · Peru (2) · Georgia (1) · South Africa (1) · Vietnam (1)
Carole Mitnick, Sc.D (2) · Lorenzo Guglielmetti, MD (2)
PMID 31676905, PMID 34563240, PMID 35028659, PMID 38037119, PMID 39879593, PMID 40683298